A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*

Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 6, 2022

Gain insight into expert faculty perspectives as they discuss recent key studies from EHA 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: July 21, 2022

Gain insight from expert perspectives on key studies from the Pan Pacific Lymphoma Conference 2022 covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.

Matthew S. Davids, MD, MMSc Julie M. Vose, MD, MBA Released: August 30, 2022